Skip to main content
Article thumbnail
Location of Repository

Correlation of Matrix Metalloproteinases and Tissue Inhibitors of Matrix Metalloproteinase Expression in Ileal Carcinoids, Lymph Nodes and Liver Metastasis with Prognosis and Survival

By Petra Voland, Sophie Besig, Roland Rad, Thomas Braun, Dorothee M. Baur, Aurel Perren, Rupert Langer, Heinz Hoefler and Christian Prinz

Abstract

Purpose: Ileal carcinoids are gut epithelial tumors originating from serotonin-containing enterochromaffin (EC) cells. Therapeutic options for effectively inhibiting the growth and spread of metastatic carcinoids are still limited. We aimed to identify the role of matrix metalloproteinases (MMPs) and their endogenous tissue inhibitors (TIMPs) during tumor development and metastasis. Patients and Methods: Tissue samples were obtained from surgically treated patients. Expression of the EC-cell marker, vesicular monoamine transporter-1 (VMAT-1), was used to verify ileal carcinoids. We investigated the differential expression of MMP-2, 7, 9, 11, and 13 and their endogenous inhibitors (TIMP-1, 2, and 3) by quantitative real-time RT-PCR in 25 primary tumors, their corresponding lymph node metastases and/or liver metastases and matched normal mucosa. Results: Significantly increased expression of VMAT-1, MMP-2, MMP-11, TIMP-1 and TIMP-3 was determined by quantitative RT-PCR in EC-cell carcinoids compared to normal intestinal mucosa (p < 0.05). In contrast, MMP-2 and MMP-9 as well as TIMP-1, TIMP-2, and TIMP-3 expression in primary tumors of patients with liver metastases (M1) was significantly lower than in patients lacking liver metastases (M0). EC-cell tumors were significantly larger in the M1 group of tumors, while VMAT-1 expression was significantly decreased. We found an inverse correlation between tumor size and prognosis. Univariate analysis further revealed that decreased expression of VMAT-1, MMP-2 and TIMP-3 in primary tumors was significantly associated with a reduced survival time of the patients. Conclusion: Our data reveal that MMP-2 and TIMP-3 expression together with VMAT-1 expression are of potential prognostic and clinical value in ileal carcinoids. Copyright (C) 2008 S. Karger AG, Basel

Topics: Medizin, ddc:610
Publisher: Ludwig-Maximilians-Universität München
Year: 2009
DOI identifier: 10.1159/000151482
OAI identifier: oai:epub.ub.uni-muenchen.de:16572
Provided by: Open Access LMU

Suggested articles

Citations

  1. C: CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo.
  2. (2006). C: MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer.
  3. (1997). Classification of neuroendocrine tumors of the gastrointestinal tract and pancreas and its therapeutic relevance (in German). Chirurg
  4. (2002). Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene
  5. (1996). E: Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.
  6. (2005). Eisenhofer G: Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.
  7. (1998). Garbisa S: Augmented membrane type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis. Clin Cancer Res
  8. (1997). Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors. Mod Pathol
  9. (1999). GI: Matrix metalloproteinases in tumour invasion and metastasis.
  10. (2006). HR: Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev
  11. Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1.
  12. (1995). Kloppel G: Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch
  13. (2003). Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development.
  14. (1997). Matrix metalloproteinases and tissue inhibitors of metalloproteinases in thyroid C-cells and medullary thyroid carcinomas. Histopathology
  15. (2003). Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res
  16. O: Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours.
  17. (2004). Petitfrere E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol
  18. (2003). Physiology of gastric enterochromaffin-like cells. Annu Rev Physiol
  19. (2002). Sch ep p W , Beck e r I , W agn e r H , Prinz C: The Helicobacter pylori blood group antigen-binding adhesin facilitates bacterial colonization and augments a nonspecific immune response.
  20. (1997). Sobin LH: Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer
  21. (2007). Sobin LH: From the archives of the AFIP: gastrointestinal carcinoids: imaging features with clinicopathologic comparison. Radiographics
  22. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res
  23. Taal BG: Metastatic carcinoid tumors: a clinical review. Oncologist
  24. (2005). Viale G: A subset of highgrade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression. Virchows Arch
  25. Wiedenmann B: TNM staging of foregut (neuro)-endocrine tumors: a consensus proposal including a grading system. Virchows Arch
  26. (2007). Wiedenmann B: TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.